News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
New and experimental HIV treatments
Nanoparticles May Transport HIV Meds to the Brain

Researchers have had early success in a method that might one day thwart the powerful blood-brain barrier and effectively deliver antiretrovirals to the brain.

Published
16 May 2013
From
AIDSMeds
The search for a cure
UPDATE: Sangamo Highlights Encouraging Preliminary Anti-Viral HIV Data

he data, which demonstrate that SB-728-T treatment results in a reduction in the HIV reservoir in HIV-infected subjects, are being presented at the 16^th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).

Published
15 May 2013
From
Benzinga
New and experimental HIV treatments
Protease Inhibitors Boost Levels of Cenicriviroc, a CCR5/CCR2 Antagonist

Ritonavir, darunavir/ritonavir, and atazanavir/ritonavir all more than tripled exposure of cenicriviroc, an investigational CCR5 and CCR2 receptor antagonist, in 60 healthy volunteers. There were no serious or unexpected adverse events in these 20-day studies.

Published
14 May 2013
From
NATAP
Pharmaceutical industry
Johnson & Johnson allies with biotech startup on HIV drug in China

The biopharma startup Ascletis has snagged exclusive rights from Johnson & Johnson's ($JNJ) Janssen for an experimental HIV protease inhibitor for the China market. Hangzhou, China-based Ascletis aims to develop the candidate, called TMC310911.

Published
01 May 2013
From
FierceBiotech
New and experimental HIV treatments
FDA rejects two of the four drugs in Gilead's blockbuster HIV drug Stribild

The FDA has handed back a pair of new drug applications from Gilead ($GILD) covering key products used in its blockbuster four-in-one HIV-fighting therapy Stribild.

Published
30 April 2013
From
FierceBiotech
Vaccines
Researchers stop the only current HIV vaccine efficacy trial

The US National Institute of Allergy and Infectious Diseases (NIAID) has announced that it is discontinuing the HVTN 505 HIV vaccine trial. This trial, which started in July

Published
26 April 2013
By
Gus Cairns
The search for a cure
Doctors' historic effort to cure child with HIV and leukemia

A University of Minnesota team performed an unprecedented transplant on Tuesday in an effort to cure a 12-year-old boy who has both HIV and leukemia. Their potential solution: umbilical cord blood containing a protein known to protect a person against HIV.

Published
25 April 2013
From
MPR News
New and experimental HIV treatments
New nanotechnique to deliver life-saving drugs to the brain

In a study published in today's issue of Nature Communications, researchers from FIU's Herbert Wertheim College of Medicine describe a revolutionary technique they have developed that can deliver and fully release the anti-HIV drug AZTTP into the brain.

Published
22 April 2013
From
Phys.org
Finance and funding
Preparing for Generics: The push for affordable HIV treatment doesn’t end with patent expirations

The United States is on course for some much-needed economic relief from the crippling cost of HIV treatment, with the anticipated arrival of generic versions of guidelines- preferred antiretrovirals. However, much preparation is required to maximize price competition, maintain patient choice, and ensure that savings are used to the advantage of people living with HIV.

Published
11 April 2013
From
Treatment Action Group
New and experimental HIV treatments
DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs

The focus of the joint R&D effort is to expedite research into and the development of new maturation inhibitor drugs by combining DFH Pharma's background and experience in HIV therapeutic development with Hetero's world class expertise in product development, medicinal chemistry, manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms.

Published
04 April 2013
From
DFH Pharma press release
← First12345...67Next →

Filter by country